Proton arc therapy and associated improvements in quality-adjusted life expectancy for head-and-neck cancer patients compared to volumetric modulated arc therapy and intensity-modulated proton therapy

<i>Objective.</i>Proton arc therapy (PAT), which relies on target irradiation from arc trajectories rather than just a few angles, is currently under investigation and has demonstrated dosimetric benefits over current clinical intensity-modulated proton therapy (IMPT) in numerous<i>in silico</i>studies. However, the resulting impact on the patient's quality-adjusted life expectancy (QALE), which takes into account quality-of-life reductions resulting from e.g. healthy tissue toxicities, remains to be investigated. This study aims to compare photon-based volumetric modulated arc therapy (VMAT) to IMPT and PAT with respect to the associated QALE.<i>Approach.</i>For each of 20 patients with head-and-neck cancer, three treatment plans (VMAT, IMPT, and PAT) were generated, and a Markov model was constructed to simulate the associated QALE. The model-iterations of which have previously been used for comparisons of photon and proton therapy (but not PAT)-considered the calculated tumor control probability, the probability of healthy tissue toxicities, metastases, and/or secondary cancer, and death from primary cancer, secondary cancer, metastases, or unrelated causes. For all patients and treatment plans, 10 000 simulations of the patient's entire lifespan subsequently to treatment were performed.<i>Main results.</i>Mean values and standard deviations of IMPT and PAT QALE improvements relative to VMAT were (0.1 ± 0.2) quality-adjusted life years (QALYs) and (0.3 ± 0.2) QALY, respectively. The highest benefits observed were 0.5 QALY in the case of IMPT and 1.0 QALYs in the case of PAT, equivalent to 6.0 months and 12.0 months of life in perfect health. Compared to IMPT, PAT improved QALE by up to 0.8 QALYs (9.6 months; (0.2 ± 0.2) QALY).<i>Significance.</i>PAT was associated with higher QALE values in all 20 cases compared to VMAT and IMPT. In 12 cases, the QALE benefits of utilizing PAT rather than IMPT consistently exceeded the benefits of utilizing IMPT rather than VMAT.

Authors

Institutions

Publication Details

Journal
Physics in Medicine and Biology
Published
2025-12-02
DOI
https://doi.org/10.1088/1361-6560/ae2739
Primary Topic
Radiation Therapy and Dosimetry
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Proton arc therapy and associated improvements in quality-adjusted life expectancy for head-and-neck cancer patients compared to volumetric modulated arc therapy and intensity-modulated proton therapy

Peilin Liu, Cornelia Hoehr, Xuanfeng Ding, Sebastian Tattenberg et al.
Physics in Medicine and Biology
Radiation Therapy and Dosimetry
article

Proton arc therapy and associated improvements in quality-adjusted life expectancy for head-and-neck cancer patients compared to volumetric modulated arc therapy and intensity-modulated proton therapy

Peilin Liu, Cornelia Hoehr, Xuanfeng Ding, Sebastian Tattenberg, Anthony Mulhem, Xiaoda Cong, Evan Harbert
article en

Abstract

<i>Objective.</i>Proton arc therapy (PAT), which relies on target irradiation from arc trajectories rather than just a few angles, is currently under investigation and has demonstrated dosimetric benefits over current clinical intensity-modulated proton therapy (IMPT) in numerous<i>in silico</i>studies. However, the resulting impact on the patient's quality-adjusted life expectancy (QALE), which takes into account quality-of-life reductions resulting from e.g. healthy tissue toxicities, remains to be investigated. This study aims to compare photon-based volumetric modulated arc therapy (VMAT) to IMPT and PAT with respect to the associated QALE.<i>Approach.</i>For each of 20 patients with head-and-neck cancer, three treatment plans (VMAT, IMPT, and PAT) were generated, and a Markov model was constructed to simulate the associated QALE. The model-iterations of which have previously been used for comparisons of photon and proton therapy (but not PAT)-considered the calculated tumor control probability, the probability of healthy tissue toxicities, metastases, and/or secondary cancer, and death from primary cancer, secondary cancer, metastases, or unrelated causes. For all patients and treatment plans, 10 000 simulations of the patient's entire lifespan subsequently to treatment were performed.<i>Main results.</i>Mean values and standard deviations of IMPT and PAT QALE improvements relative to VMAT were (0.1 ± 0.2) quality-adjusted life years (QALYs) and (0.3 ± 0.2) QALY, respectively. The highest benefits observed were 0.5 QALY in the case of IMPT and 1.0 QALYs in the case of PAT, equivalent to 6.0 months and 12.0 months of life in perfect health. Compared to IMPT, PAT improved QALE by up to 0.8 QALYs (9.6 months; (0.2 ± 0.2) QALY).<i>Significance.</i>PAT was associated with higher QALE values in all 20 cases compared to VMAT and IMPT. In 12 cases, the QALE benefits of utilizing PAT rather than IMPT consistently exceeded the benefits of utilizing IMPT rather than VMAT.

Physics in Medicine and BiologyVol. 70(24)
TRIUMF (CA), Beaumont Health (US), Beaumont Hospital, Royal Oak (US), Laurentian University (CA), Michigan State University (US)
Openalex Percentile: Top 44%
Radiation Therapy and Dosimetry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.